A Capsule for Sleep Apnea? Medical Trial Yields Promising Outcomes

Hundreds of thousands of individuals within the U.S. have sleep apnea, most of whom aren’t getting handled for it. However a easy every day capsule of an outdated drug simply may assist individuals with the situation, current trial knowledge reveals.

Scientists in Sweden and elsewhere have been finding out the anti-seizure treatment sultiame as a remedy for obstructive sleep apnea. Of their newest Section II trial, they discovered that individuals on sultiame skilled a big enchancment of their apnea signs and sleep high quality in comparison with these taking a placebo. The outcomes recommend sultiame might grow to be an efficient possibility for sleep apnea, significantly for these unable to tolerate steady optimistic airway strain (CPAP) machines, the researchers say.

“These findings provide views for a pharmaceutical strategy to remedy of sufferers with obstructive sleep apnea,” they wrote of their paper, published in The Lancet.

A capsule for apnea?

Obstructive sleep apnea, or OSA, is the commonest type of sleep apnea, affecting roughly 12% of U.S. adults. It occurs when airway muscle tissues bodily block an individual’s respiration throughout sleep. This pause causes the physique to get up simply sufficient to begin respiration once more, just for the cycle to restart all through the night time—anyplace from 5 to 100 occasions an hour. These episodes trigger low oxygen ranges and disturb individuals’s sleep and, over time, can elevate the danger of different long-term well being issues, together with heart disease and presumably even dementia.

CPAP machines use air strain to maintain the airways open throughout sleep and generally is a extremely efficient apnea remedy. Although these machines have gotten simpler to put on over time, many individuals nonetheless have bother utilizing them long-term or have a medical situation that stops their use. And that’s led some corporations to pursue less cumbersome interventions, together with drugs.

Bayger AG first launched sultiame (additionally known as sulthiame) within the Nineteen Sixties as an anticonvulsant, and it’s nonetheless used as such in lots of European international locations (the drug was by no means accepted in America). The drug works by inhibiting carbonic anhydrase, an enzyme that performs a task in regulating our respiration. And early analysis has urged the drug can stabilize the respiration of individuals with apnea throughout sleep, thus stopping airway collapse. The U.S.-based Apnimed, at the side of the Japanese firm Shionogi & Co., Ltd., have been seeking to develop sultiame as a sleep apnea remedy.

The section II trial concerned 298 sufferers with untreated, average to extreme sleep apnea. Over a 15-week interval, half had been randomized to a placebo capsule taken proper earlier than mattress, whereas the remainder got various doses of sultiame. Individuals taking sultiame noticed a noticeable lower of apnea episodes, the researchers discovered, together with enhancements of their sleep high quality and daytime sleepiness. Individuals within the highest dose group noticed the most important enchancment, as much as a 47% discount in apnea occasions.

“It seems like a breakthrough, and we now look ahead to bigger and longer research to find out whether or not the impact is sustained over time and whether or not the remedy is protected for broader affected person teams,” mentioned research researcher Jan Hedner, a senior professor of pulmonary drugs on the College of Gothenburg, in an announcement from the college released on Wednesday.

The way forward for apnea remedy

Sultiame isn’t the one pill-based remedy being studied for apnea.

In late 2024, Eli Lilly secured an expanded approval of its GLP-1 treatment tirzepatide to deal with sleep apnea as nicely (weight problems is a serious threat issue of OSA, and weight reduction can cut back its signs). Apnimed can also be creating different medication that it hopes can deal with the foundation causes of apnea. Its high candidate, code-named AD109, has already shown optimistic leads to Section III trial knowledge, and the corporate plans to formally search FDA approval for AD109 someday this yr.

Hopefully, within the close to future, individuals with apnea may have a bevy of choices out there to ward off their sleepless nights.